Beijing Science Sun Pharmaceutical Co Ltd (SHE:300485) — Market Cap & Net Worth
Market Cap & Net Worth: Beijing Science Sun Pharmaceutical Co Ltd (300485)
Beijing Science Sun Pharmaceutical Co Ltd (SHE:300485) has a market capitalization of $592.76 Million (CN¥4.05 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #11458 globally and #3241 in its home market, demonstrating a -0.59% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beijing Science Sun Pharmaceutical Co Ltd's stock price CN¥8.41 by its total outstanding shares 481666400 (481.67 Million). Also see Beijing Science Sun Pharmaceutical Co Lt assets under control for a full breakdown of the balance sheet.
Beijing Science Sun Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Beijing Science Sun Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.42 Billion to $592.76 Million (-7.50% CAGR). Also see Beijing Science Sun Pharmaceutical Co Lt (300485) cash flow conversion for how efficiently the company converts equity into cash flow.
Beijing Science Sun Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beijing Science Sun Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 300485 live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.84x
Beijing Science Sun Pharmaceutical Co Ltd's market cap is 1.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
51.18x
Beijing Science Sun Pharmaceutical Co Ltd's market cap is 51.18 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.42 Billion | $616.24 Million | $258.41 Million | 2.30x | 5.49x |
| 2017 | $960.69 Million | $749.99 Million | $281.60 Million | 1.28x | 3.41x |
| 2018 | $660.12 Million | $1.43 Billion | $283.11 Million | 0.46x | 2.33x |
| 2019 | $613.30 Million | $1.19 Billion | $148.64 Million | 0.51x | 4.13x |
| 2020 | $1.01 Billion | $1.09 Billion | $154.90 Million | 0.92x | 6.51x |
| 2021 | $906.29 Million | $1.05 Billion | $402.27 Million | 0.86x | 2.25x |
| 2022 | $835.15 Million | $734.55 Million | $204.73 Million | 1.14x | 4.08x |
| 2023 | $744.12 Million | $476.57 Million | $102.92 Million | 1.56x | 7.23x |
| 2024 | $494.09 Million | $416.48 Million | -$68.85 Million | 1.19x | N/A |
| 2025 | $745.71 Million | $404.72 Million | $14.57 Million | 1.84x | 51.18x |
Competitor Companies of 300485 by Market Capitalization
Companies near Beijing Science Sun Pharmaceutical Co Ltd in the global market cap rankings as of September 19, 2026. Review Beijing Science Sun Pharmaceutical Co Lt (300485) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Beijing Science Sun Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Beijing Science Sun Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Beijing Science Sun Pharmaceutical Co Ltd's market cap moved from $2.42 Billion to $ 592.76 Million, with a yearly change of -7.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥592.76 Million | -20.51% |
| 2025 | CN¥745.71 Million | +50.93% |
| 2024 | CN¥494.09 Million | -33.60% |
| 2023 | CN¥744.12 Million | -10.90% |
| 2022 | CN¥835.15 Million | -7.85% |
| 2021 | CN¥906.29 Million | -10.15% |
| 2020 | CN¥1.01 Billion | +64.47% |
| 2019 | CN¥613.30 Million | -7.09% |
| 2018 | CN¥660.12 Million | -31.29% |
| 2017 | CN¥960.69 Million | -32.24% |
| 2016 | CN¥1.42 Billion | -41.48% |
| 2015 | CN¥2.42 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Beijing Science Sun Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $592.76 Million USD |
| MoneyControl | $592.76 Million USD |
| MarketWatch | $592.76 Million USD |
| marketcap.company | $592.76 Million USD |
| Reuters | $592.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Beijing Science Sun Pharmaceutical Co Ltd
Beijing Science Sun Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of injections in China. The company offers products for cardiovascular, cerebrovascular, immunomodulation, and nervous systems, and other drugs. It is also involved in raw materials, solid oral preparations, and health products; extraction of traditional Chinese me… Read more